BREAST CANCER

KEYNOTE-756 is the first positive phase 3 study to generate a statistically significant improvement in pathological complete response rate with an immunotherapy regimen in the neoadjuvant setting for ER-positive/HER2-negative breast cancer.

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth Mittendorf, MD, discussed how antibody-drug conjugates fit into the treatment algorithm for patients with advanced breast cancers.

In an interview with Targeted Oncology, Hope S. Rugo, MD, explained the results of the phase 3 CAPItello-291 trial, and the potential impact of the study on the breast cancer treatment paradigm.

Health-related quality of life measures from the phase 3 DESTINY-Breast03 trial showed that patient-reported outcomes and time of hospitalization data favored trastuzumab deruxtecan despite having a longer duration of treatment than trastuzumab emtansine.

In an interview with Targeted Oncology, Daniel G. Stover, MD, highlighted the objective to enhance delivery of endocrine therapy plus CDK4/6 inhibitors to patients with hormone receptor-positive, HER2-negative breast cancer by utilizing biomarker assessments as a guide to interchange or cease treatment at the most favorable time.

Closing out his discussion on HR+/HER2- metastatic breast cancer, Kevin Kalinsky, MD, MS, highlights key takeaways and shares excitement for future evolutions in the treatment paradigm.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hatem Soliman, MD, discussed how the FDA approval of elacestrant impacts the treatment setting of ER+, HER2- breast cancer

An investigation of treatment with concurrent paxalisib and whole brain radiotherapy is underway in a phase 1 clinical trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed the use of elacestrant for patients who have received prior endocrine therapy for ER-positive, HER2-negative breast cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial of sacituzumab govitecan for patients with hormone receptor–positive, HER2-negative breast cancer.

Data from the phase 3 CAPItello-291 trial of capivasertib plus fulvestrant in HR-positive, HER2-negative locally advanced or metastatic breast cancer have led the FDA to grant priority review to the new drug application for the combination.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.

Lasofoxifene in combination abemaciclib showed antitumor activity that was not compromised by co-occuring alterations that confer endocrine resistance.

A sustained overall survival benefit has been reported from the phase 3 TROPiCS-02 study.

Patritumab deruxtecan treatment yielded efficacy results and was safe for patients with metastatic breast cancer.

A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression-free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.

Dennis J. Slamon, MD, discusses the key findings from the phase 3 NATALEE trial of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.

Results from an age group analysis of the monarch E trial reveal continued efficacy and safety with the experimental regimen, abemaciclib plus endocrine therapy.

Findings presented at a press briefing during the 2023 ASCO Annual Meeting revealed that the primary end point was met in the phase 3 NATALEE trial.

Adam Brufsky, MD, PhD, FACP, discusses background and previous clinical data on palbociclib as a treatment option for patients with estrogen receptor-positive, HER2-negative, advanced breast cancer.

In an interview with Targeted Oncology, Andreas Varkaris, MD, PhD, discussed findings from the ReDiscover trial and treating patients with PIK3CA mutations.

The FDA has requested additional information regarding vic-trastuzumab duocarmazine to further evaluate the agent for patients with HER2-positive metastatic breast cancer.

During a Targeted Oncology™ Clinical Case Forum™ event, Terry P. Mamounas, MD, MPH, discussed the treatment landscape for patients with HER2-positive breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.